Potential role of immunotherapy in advanced non-small-cell lung cancer

Immuno checkpoint inhibitors have ushered in a new era with respect to the treatment of advanced non-small-cell lung cancer. Many patients are not suitable for treatment with epidermal growth factor receptor tyrosine kinase inhibitors (eg, gefitinib, erlotinib, and afatinib) or with anaplastic lymph...

Descripción completa

Detalles Bibliográficos
Autores principales: de Mello, Ramon Andrade, Veloso, Ana Flávia, Esrom Catarina, Paulo, Nadine, Sara, Antoniou, Georgios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5179204/
https://www.ncbi.nlm.nih.gov/pubmed/28031719
http://dx.doi.org/10.2147/OTT.S90459

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5179204/
https://www.ncbi.nlm.nih.gov/pubmed/28031719
http://dx.doi.org/10.2147/OTT.S90459

Ejemplares similares